HRS-9563

· Fujian Shengdi Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HRS-9563, covering 2025-08-12 to 2026-01-26. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension [Phase 2]